Today, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced that they will be hosting a Clinical Research Day on December 15th. The purpose of Zynerba's event is to discuss "the potential role that ZYN002 CBD gel may play in providing relief for patients with debilitating conditions including epilepsy, osteoarthritis and Fragile X syndrome."
ZYN002 CBD Gel
ZYN002 CDB gel is absorbed through the skin or transdermally, rather than orally or otherwise. This allows for better absorption of the cannabinoids. This will allow for a more sustained, consistent, and controlled delivery method for cannabinoid treatment.
Attending
The event will be held in New York City from 8:00 AM EST to 10:30 AM EST. Zynerba management as well as industry opinion leaders will be present and sharing their thoughts. Those interested in attending the event should contact Janet Cushey from Argot Partners at 212-600-1902 or janet@argotpartners.com. For those who wish to listen in via live webcast will be able to stream it from the investor relations section of Zynerba's website on the 15th and for 90 days following the event.
Conclusion
For more information and custom stock charts for ZYNE, be sure to check out Zynerba Pharmaceuticals' stock profile in our marijuana stocks database. Also, don't forget to connect with us on social media using the links to the right of this article so you never miss a marijuana stock update. For Zynerba's press release regarding the Clinical Research Day, click here.
